
via University of Turku
A research group at the University of Turku has led the development of a new method to evaluate vaccine safety. The new method may significantly reduce the use of animal testing in the vaccine industry.
Vaccines are safe and potent pharmaceutical products that prevent infectious diseases caused by viruses and bacteria, and reduce the spread of pathogens among the population. A vaccine prevents an infectious disease because the body develops an ability to recognise and destroy the pathogen. Vaccines are generally designed from a weakened pathogen, or parts of it. The vaccine industry uses effective methods to ensure vaccine safety, and constantly develops new methods as well.
The pertussis vaccine, which also belongs to the Finnish national vaccination programme, contains the surface structures of the pertussis bacteria and inactivated forms of the pertussis toxin produced by the bacteria. The pertussis toxin attaches to the surface of the cell, penetrates it, and destroys the vital control system of the cell.
The research group at the University of Turku has led the development of the new method that can be used to ensure the safety of the pertussis toxin in the pertussis vaccine. The new iGIST method (Interference in G?i-mediated Signal Transduction) detects how the pertussis toxin destroys the vital control system of the cell.
– Compared to the current methods in the vaccine industry, iGIST is more effective and enables the detection of up to 100 times lower levels of pertussis toxin. iGIST is entirely based on using laboratory grown, human-based cells. Therefore, it may significantly reduce the use of animal testing in the vaccine industry, says Dr Arto Pulliainen from the University of Turku who was the principal investigator of the research group that was in charge of developing the method.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Vaccine safety
- Veterinary Vaccines Industry Gears Up to Surpass a Noteworthy US$ 20.82 Billion by 2033-FMI Report
By 2033, it is expected that the veterinary vaccines industry would have grown from US$ 11.3 billion in 2023 to approximately US$ 20.82 billion. This is anticipated to propel veterinary vaccines’ ...
- Kenya spearheads malaria vaccine triumph
Malaria burden is the highest on the African continent, which accounts for approximately 95% of global malaria cases and 96 percent of related deaths in 2021.
- Ken Paxton sues Pfizer over alleged misrepresentation of COVID-19 vaccine efficacy
Texas Attorney General Ken Paxton announced Thursday the state was suing the pharmaceutical giant Pfizer for allegedly misrepresenting the effectiveness of its COVID-19 vaccine and attempting to ...
- Texas AG sues Pfizer over Covid-19 vaccine effectiveness claims
Paxton is focusing on a claim touted by Pfizer in 2020 that its Covid vaccine was 95% effective, leaving the impression that the vaccine “would end the coronavirus pandemic and lift the omnipresent ...
- Texas Attorney General Sues Pfizer Over ‘Misleading’ COVID Vaccine
Attorney General Ken Paxton said the pharma giant misled consumers about the efficacy of its vaccines before pivoting to “silencing truth-tellers.” ...
Go deeper with Google Headlines on:
Vaccine safety
[google_news title=”” keyword=”vaccine safety” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Vaccine safety evaluation
- Texas AG Ken Paxton sues Pfizer for ‘misrepresenting’ COVID vaccine efficacy
That conclusion was made based on their evaluation of 170 confirmed COVID cases ... the patients it serves and has no higher priority than the safety and effectiveness of its treatments and vaccines,” ...
- Texas AG Sues Pfizer, Alleging Company Made ‘Deceptive’ Claims about Covid-19 Vaccine Efficacy
The AG’s office said Pfizer’s claim that its vaccine is 95 percent effective against Covid-19 infection is ‘highly misleading.’ ...
- GSK CEO says RSV vaccine revenue to top 1 billion pounds in first year
NEW YORK/LONDON (Reuters) -GSK CEO Emma Walmsley gave an upbeat assessment of the British drugmaker's new respiratory syncytial virus (RSV) vaccine on Thursday and said the costs of Zantac litigation ...
- Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate
Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant proteinC1-cell produced antigen was both safe and well-toleratedNo Serious Adverse Events reportedFinal Clinical ...
- African swine fever vaccines yet to be fully understood
Many livestock companies are still confused about using the African swine fever vaccine for their pig herds, despite government approval.
Go deeper with Google Headlines on:
Vaccine safety evaluation
[google_news title=”” keyword=”vaccine safety evaluation” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]